Ligand announces OmniAb® partnership with Genagon Therapeutics
Ligand announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics. Under the terms, Genagon gains access to the full OmniAb platform including OmniRat®. Ligand received an upfront payment and is eligible to receive development milestone payments. February 07, 2019